Loading...
Objective and subjective measures of dalfampridine efficacy in clinical practice
BACKGROUND: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patie...
Na minha lista:
| Udgivet i: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6077903/ https://ncbi.nlm.nih.gov/pubmed/30090641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318786742 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|